Search PubMed⌕ Search

Biomedical subjects

S C Stone

Publications and source records attributed to S C Stone.

70 records · Page 4Linked to original sources
PubMed1976

LHRH and steroid levels in normal ovulatory women.

Synthetic LHRH was given intravenously in a dose of 250 mug to a group of 7 normal women in different phases of the menstrual cycle. The LH response was more pronounced in the preovulatory and luteal phase than in the follicular phase of the cycle. The FSH response was less than that of LH and was the same in all phases of the cycle. No significant changes were observed in the plasma levels of estradiol 17-beta, progesterone, or testosterone for up to 6 hours as well as 24 hours after LHRH administration in any of the subjects studied. In 2 of 3 subjects, administration of LHRH in the luteal phase resulted in the prolongation of the cycle. No effect on cycle length was observed when LHRH was given at other times of the cycle. LHRH did not affect the length of the subsequent cycle regardless of the day of administration.

Adult↗
PubMed1976

Effect of bromo-ergocryptine on serum hPRL, hLH, hFSH, and estradiol 17-beta in women with galactorrhea-amenorrhea.

Fourteen women with amenorrhea-galactorrhea were treated with bromo-ergocryptine. Serum prolactin hPRL, hLH, hFSH, estradiol 17-beta (E2), and progesterone values were determined before and during treatment. No consistent pretreatment hormonal pattern was found. During treatment hPRL levels fell in 13 of 14 patients, and E2 rose in 12 of 14 patients. Levels of hLH became normal, and amounts of hFSH did not change. Galactorrhea lessened in all cases and ceased in 11. Menses resumed in 11 patients and 3 women became pregnant. Cessation of galactorrhea and resumption of menses occurred irrespective of initial hPRL or hLH levels. It is suggested that improvement of galactorrhea and resumption of menses in some patients with normal hPRL values are the result of increased serum E2 levels and may be due to a direct action of bromo-ergocryptine on the ovary. Bromo-ergocryptine may also be effective in treatment of amenorrhea, unassociated with galactorrhea or elevated hPRL levels.

Adult↗
PubMed1975

The acute effect of hysterectomy on ovarian function.

The acute effect of abdominal and vaginal hysterectomy on the ovarian production of estradiol-17-beta (E2) and progesterone (P) was studied in a group of patients undergoing hysterectomy for various gynecologic indications. Plasma levels of steroids as well as gonadotropins (FSH and LH) were measured by RIA. There was a significant but transient drop of plasma E2 during the follicular phase and of plasma E2 and P during the luteal phase, following hysterectomy. No significant variations in the steroid plasma levels were found in a control group of patients undergoing laparoscopy for diagnostic purposes. No changes were noted in either group in the plasma levels of gonadotropins. The changes seen appear to be related to the surgical manipulation in the ovarian region rather than to the type of hysterectomy performed or the stress of surgery.

Adult↗
PubMed1975

Postmenopausal symptomatology, maturation index, and plasma estrogen levels.

An attempt to correlate postmenopausal symptoms with the vaginal maturation index and plasma levels of estrogen was made in a group of patients with surgical menopause. The group was followed up monthly for 6 months in a double-blind study during which the patients received equine esterified estrogen and synthetic esterfield estrogens. No statistical difference in plasma levels of estrogen was found between the group of patients with symptoms and the patients without symptoms, with or without estrogen therapy. There was no correlation of the maturation index with the presence or absence of symptoms or with the estrogen plasma levels.

Adult↗
PubMed1975

Effect of adrenal suppression in gonadal gysgenesis.

Plasma steroids, estrogen, progesterone, and testosterone, and plasma gonadotropins FSH and LH were determined before and after adrenal suppression in an 18-year-old patient with gonadal dysgenesis (XX/XO). Total plasma estrogen was initially low (9.2 plus or minus 2.4 pg/ml) and did not change after adrenal suppression. Plasma progesterone (380 plus or minus 18 pg/ml) and testosterone (236 plus or minus pg/ml) were in the range found in the normal follicular phase and fell to 50 plus or minus 17 pg/ml and 112 plus or minus pg/ml, respectively, after adrenal suppression. Mean levels of FSH and LH were unchanged after adrenal suppression. These results suggest that the adrenal may make a significant contribution to plasma levels of progesterone and testosterone in patients with gonadal dysgenesis and may also contribute to the plasma levels of these steroids during the follicular phase of the mensturual cycle.

Adolescent↗
PubMed1974

Effect of Lh-Rh on antibody formation, sperm count and plasma levels of gonadotropins and testosterone in normal men.

Synthetic LH-RH was given to 15 healthy men divided into 3 groups of 5 each. A dose of 250 mug LH-RH was injected as a single intravenous bolus for 1 day, every other day for 3 days or for 7 consecutive days respectively. Antibody formation against this synthetic hormone was measured by testing for binding with 125I labeled LH-RH. No antibody formation was detected in any group during the seven day period. Sperm counts were done 1 week before and immediately after the administration of LH-RH, as well as 3 months later. Changes in sperm counts could not be related to the number of injections received. Gonadotropins (FSH and LH) were measured by RIA. There was a significant rise in plasma levels of both gonadotropins, but no signigicant changes in their basal level or percent response resulted from the repetitive administration of LH-RH. Plasma testosterone was also measured by RIA. There was no significant channge in either baseline or percent response in any of the groups after 1, 3 or 7 injections. Some individuals did show a significant rise in plasma testosterone levels, but this was not consistent and was not related to the number of injections administered. Thus, in this study, the repetitive administration of LH-RH did not alter pituitary responsiveness or result in antibody formation.

Adolescent↗
PubMedDate not supplied

Relationship between serum estradiol concentration and IGF-I, IGF-II and IGF-binding proteins in patients with premature ovarian failure on short-term estradiol therapy.

OBJECTIVE: Insulin-like growth factors (IGFs) exert stimulatory effects on follicular growth and development, and early embryogenesis. In view of this, we studied the effect of short-term estradiol treatment, as used in preparing the uterus for embryo implantation, on the serum concentrations of IGFs and their binding proteins (IGFBP) in patients with premature ovarian failure (POF). PATIENTS AND METHODS: Twenty-four patients with POF, enrolled in an assisted reproduction program, were treated with increasing doses of estradiol up to 8 mg daily for 6 weeks. Blood was sampled for measurement of serum estradiol, IGF-I, IGF-II, and IGFBP 1, 2 and 3 at various times during estradiol treatment. RESULTS: There was no significant correlation between serum estradiol concentrations and the serum concentrations of IGF-I and IGF-II. As expected, IGF-I and IGF-II concentrations in serum correlated positively with the serum concentration of IGFBP-3, the major IGF-binding protein in serum. CONCLUSION: The results of this study suggest that estradiol therapy as used to prepare the uterus for implantation has no significant effect on serum IGF-I and IGF-II concentrations, and therefore probably does not influence, via an IGF-mediated mechanism, the success of implantation and early embryonic development.

Adult↗